The benefits of the vaccine developed by the University of Oxford and the pharmaceutical AstraZeneca to combat Covid-19 they outweigh their risks. This was stated this Wednesday at a press conference by Dr. Jane Raine, director of the Regulatory Agency for Medicines and Health Products (MHRA) of the United Kingdom, just a few minutes after the European Medicines Agency (EMA) confirmed “a possible link” of the vaccine with a series of rare cases of thrombosis reported in people who received the immunization.
Raine acknowledged that there is a “great chance” that the vaccine causes ‘extremely rare’ blood clotting side effects, but he clarified that “no effective vaccine or drug is risk-free” and that “clinical trials allow us to find common side effects”, while “rare side effects only become evident when a large number of people are vaccinated.”
Until now, more than 20 million people have received the AstraZeneca vaccine in the UK, 19 of which died from thrombi out of 79 cases detected up to March 31, making it an “extremely rare” consequence, Raine considered, who explained that the risk, considering these figures, is 4 people per million .
“The balance between the known benefits and risks of the vaccine remains very favorable for most people,” said the doctor. However, based on the data studied, the organism recommended to the Government a change in its vaccination campaign, so that adults under 30 years of age are injected, whenever possible, with an alternative vaccine instead of AstraZeneca’s. In any case, the general vaccination of that age group has not yet begun, with the exceptions in those who suffer from other conditions that required early vaccination, and the regulator was clear that they do not recommend the suspension of the use of the vaccine in any other age group.
Professor Munir Pirmohamed, Chairman of the Commission for Human Medicine in the United Kingdom, stated for his part that pregnant women should discuss the risks with their doctor, and that those with a history of blood disorders should only use this vaccine after evaluating whether the benefits outweigh the risks in their case. “Anyone who has clotting episodes” after the first dose “You should not wear the second”, Pirmohamed said, noting that people have “a much higher risk of developing clots if they get Covid-19.”
England’s Deputy Chief Medical Officer Professor Jonathan Van-Tam explained that ‘in a low-exposure scenario, where Covid-19 rates are lower than current rates in the UK, for people aged 20 to 29 the risk-benefit is relatively well balanced ”, but in older age groups, the numbers are “overwhelmingly in favor” of the vaccine. And in the event of a high risk of exposure, comparable to the second wave, it ensures that even in the 20-29 age group the potential benefits “in terms of avoiding intensive care admissions are much higher” than the possible harms. severe caused by the vaccine.
George is Digismak’s reported cum editor with 13 years of experience in Journalism